IMC-C103C
- Generic Name
- IMC-C103C
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Phase 1
Withdrawn
- Conditions
- Select Advanced Solid Tumors
- Interventions
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 75
- Registration Number
- NCT03973333
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸The University of Chicago Medicine & Biological Sciences, Chicago, Illinois, United States
🇺🇸Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath